|
|
|
| home > ebr > Spring 2016 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
Editor’s Letter
EBR’s Editor Deborah O’Neil ponders the impact of the digital age on pharma and the improved data handling this facilitates, along with other focus features in this edition.
|
|
|
|
|
Wearable Technology
Technically Speaking
Despite the growing popularity of health technologies, much uncertainty still surrounds digital healthcare and the exact definition of this ever-expanding field, say CMS Life Sciences Group’s Sarah Hanson and Laura Lucy.
|
|
|
Smart Healthcare
Intelligent Design
The Internet of Things is the latest wave of technology sweeping the healthcare landscape, observes Jonathan Wilkins at European Automation – who assesses some of the radical and potentially life-saving technologies it could bring.
|
|
|
Automation Advances
Rise of the Machines
Recent advances in cognitive computing could drastically shake up the industry, states IBM's Institute for Business Value’s Heather Fraser, enabling fast and more accurate decisionmaking by healthcare professionals to enhance patient care.
|
|
|
|
|
Biologics Characterisation
Compare the Market
The characterisation of biological products has become ever-more reliant on advanced technology, states Fredrik Sundberg at GE Healthcare. He explains why surface plasmon resonance and sensorgram comparison offer vast benefits.
|
|
|
Molecular Analysis
Measuring Up Nicely
A “fast, absolute and inherently simple method”, the emerging Taylor dispersion analysis system offers unique benefits compared to other long-established techniques, say Dr Steve Carrington and Dr Lisa Newey-Keane at Malvern Instruments.
|
|
|
Microscopy Advances
Culture Shift
The modern cell culture microscope is continuing to assist researchers improve workflow efficiency and make new discoveries. Olympus Europa’s Joachim Kirschner highlights where he believes light microscopy can take science in the near future.
|
|
|
|
Supply Chain Agility
Quick on the Draw
Agility – within all stages of pharma manufacturing – is key to achieving success in company goals, believes Mark Evenepoel at AMPLEXOR Life Sciences.
|
|
|
Sample Preservation
From Collection to Destruction
All biological samples, whether successful or not, could prove valuable in future biomarker studies – which is why extreme care must be taken when handling and transporting these highly delicate products, explains Eric Hayashi at LabConnect.
|
|
|
|
Q&A: Rare Cancer Treatments
Making Waves
As recent reports reveal that acute myeloid leukaemia – a rare cancer form – is expected to rise with an ageing population, Actinium Pharmaceuticals’ Dragan Cicic describes how a promising new radio-immunotherapy treatment could boost patient survival rates.
|
|
|
Immunotherapy Advances
Armed Against Cancer
CAR-T cell therapy – which involves engineering patients’ own immune cells to detect and attack tumours – is giving rise to a new generation of groundbreaking cancer treatments, including NKG2D, which could wipe out up to 80% of cancers, reports Christian Homsy at Celyad.
|
|
|
Oncology Research
Modify This
Alfred Hansel and Martina Schmitz at oncgnostics GmbH explain the growing popularity of epigenetic modifications in cancer treatment.
|
|
|
|
Medical Affairs
Surveying Change
Dr Fabio Gambini, Paolo Morelli and Mary Wieder at PM Clinical talks about the relatively new Medical Sciences Liaison role, and how plans to outsource this vital function could impact on the industry.
|
|
|
In Brief
Eye of the Storm
Emile Bellott comments on the growing prominence of biosimilars, which are currently gaining visibility at the highest government levels, and some of the challenges this presents.
|
|
|
|
Protein Structure
Multiple Choices
Before any biologic drug can be approved, the first crucial step is to obtain a full and accurate profile of the protein molecule – which can only be achieved by using a combination of techniques, states Ińigo Rodriguez-Mendieta at SGS.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
3P Biopharmaceuticals appoints José Luis Bartolomé as Operational Excellence Director
[Noáin, Spain, September 30, 2020]3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization
(CDMO) specialized in process development and cGMP manufacturing of
biologics, appoints a new member to the management team with the
incorporation of José Luis Bartolomé as Operational Excellence and
Continuous Improvement Director.
More info >> |
|
 |
White Papers |
 |
|
The Role of the CRO in Effective Risk-Based Monitoring
Medpace
The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >> |
|
 |
Industry Events |
 |
Pharma Integrates 2021
16 November 2021, VIRTUAL CONFERENCE
Now in its tenth year, Pharma Integrates is a unique event bringing
together pharma and healthcare leaders across the Pharmaceutical
pipeline to address their needs, to share insights and create debate on
crucial topics that influence the future of patient outcomes.
More info >> |
|
|
.jpg)
